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Available online 28 September 2014AbstractIntroduction: Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival;
however, their efficacy and safety remain unclear.
Materials and methods: The anti-tumour effects and adverse events were evaluated in 163 MIBC patients who received systemic chemo-
therapy (SC, n ¼ 34), intra-arterial chemotherapy (IAC, n ¼ 50), or combined IAC and radiotherapy (IAC þ R, n ¼ 79).
Results: Pathological complete responses were observed in 17.6%, 22.0%, and 43.0% of patients in the SC, IAC, and IAC þ R groups,
respectively, with respective 5-year overall survival rates of 42.0%, 46.7%, and 50.3%. Multivariate analysis showed that successful
IAC þ R protocol administration was a significant predictor for survival (hazard ratio ¼ 0.16, p ¼ 0.028). The incidence of severe adverse
events was higher in the IAC þ R group (36.7%) than in the SC (9.8%) and IAC groups (16.0%).
Conclusions: IAC þ R was useful for patients with MIBC. Successful completion and optimal patient selection were important for this
treatment strategy.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).
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Radical cystectomy is a conventional treatment for pa-
tients with muscle-invasive bladder cancer (MIBC). How-
ever, the high frequencies (50%) of subsequent metastasis
and local recurrence remain unresolved.1 Additionally, the
5-year survival rates after radical cystectomy for locally
invasive bladder cancer were reported to range from 35%
to 50%.2e4 Therefore, preoperative treatments are often
employed to improve survival. For this purpose,thor. Department of Nephro-Urology, Nagasaki Uni-
medical Sciences, 1-7-1 Sakamoto, Nagasaki 852-
1 95 819 8340; fax: þ81 95 819 7343.
t.doc.miya@m3.dion.ne.jp (Y. Miyata).
16/j.ejso.2014.07.043
he Authors. Published by Elsevier Ltd. This is an open acc
).chemotherapy is often administered via 2 methods, namely
systemic chemotherapy (SC) and intra-arterial chemo-
therapy (IAC). Although SC is currently common, advan-
tages of the intra-arterial method over other infusion
methods have been reported with respect to drug distribu-
tion and intratumour drug concentrations.5 Other investiga-
tors also support this finding.6 Meanwhile, combined SC
and radiotherapy is more effective against primary tumours
than is SC or radiotherapy alone.7,8 However, little informa-
tion is available regarding the superiority of and adverse
events associated with IAC and radiotherapy (IAC þ R)
versus SC or IAC monotherapy.
The main purpose of this retrospective study was to eval-
uate the safety and rates of pathological complete responseess article under the CC BY-NC-ND license (http://creativecommons.org/
362 Y. Miyata et al. / EJSO 41 (2015) 361e367(pCR) and survival after the administration of 3 different
types of preoperative chemotherapies: SC and/or radio-
therapy, IAC, and IAC þ R, in patients with MIBC. We
also analyzed the anticancer activities, including the pCR
and survival rates, according to IAC þ R intensity. Another
purpose of this study was to clarify the long-term impact of
the clinicopathological features and variables of the treat-
ment methods on the rates of these anticancer activities at
a single centre.Materials and methodsPatientsWe analyzed patients with MIBC who received pre-
operative chemotherapy at Nagasaki University Hospital
between 1988 and 2013. The final population comprised
163 patients: 130 men (79.8%) and 33 women (20.2%).
The mean age  standard deviation (SD) at the time of
treatment was 68.9  11.8 years. The patients’ clinicopath-
ological features are listed in Table 1. All pathological di-
agnoses were determined before treatment using biopsy
and/or transurethral resection (TUR) specimens. All pa-
tients were evaluated via cystoscopy, chest radiography,
bladder and renal ultrasonography, and abdominal and pel-
vic computed tomography (CT) to determine the clinical
stage. Patients with pure squamous cell carcinoma (SCC)
or adenocarcinoma, N2 or 3 staging, and M1 staging
were excluded. However, patients with N1 staging who
received treatment for downstaging were enrolled
(n ¼ 15). All patients had Grade 0e2 Eastern CooperativeTable 1
Clinicopathological features and treatment-related information.
All patients
n ¼ 163
SC
n ¼ 34
Clinicopathological; n (%)
Male 130 (79.8) 29 (76.0
Old age (>75 years) 68 (41.7) 9 (26.5
High ECOG PS (2) 14 (8.6) 3 (8.8)
Recurrent tumour 37 (22.7) 10 (29.4
With SCC/AC 16 (9.8) 5 (14.7
High grade 94 (57.7) 20 (58.8
T stage
T2 81 (49.7) 11 (32.4
T3 50 (30.7) 15 (44.1
T4 32 (19.6) 8 (23.5
High T stage (T3/4) 82 (50.3) 23 (67.6
N stage (N1) 15 (9.2) 4 (11.8
Treatment-related
Before 2002 103 (63.2) 19 (55.9
CDDP-based regimens 143 (87.7) 19 (55.9
With radiotherapy 97 (59.5) 18 (52.9
Compl TUR before chemo 72 (44.2) 13 (38.2
Cystectomy after chemo 57 (35.0) 26 (76.5
Adjuvant therapy 45 (27.6) 8 (23.5
SC, systematic chemotherapy; IAC, intra-arterial chemotherapy; R, radiotherapy
SCC, squamous cell carcinoma; AC, adenocarcinoma; CDDP, cisplatin; Compl,Oncology Group performance statuses (PS), and approxi-
mately half of the patients in our population (88/
163 ¼ 54.0%) qualified as “fully active, able to carry on
all pre-disease performance without restriction” (Grade
0). Additionally, as shown in Table 1, there was no signif-
icant difference in the high PS (Grade 2) frequency be-
tween the treatment groups. Almost all patients had
comorbidities such as hypertension and sleep disorders.
However, no patient was unable to receive chemotherapy
because of severe comorbidities.Treatment protocolInitially, we explained that radical cystectomy was the
standard method for clinically determined MIBC and was
recommended for all patients. Additionally, all patients
who did not achieve a pCR following chemotherapy were
strongly advised to undergo an additional radical cystec-
tomy at that time. Although there were no strict criteria
for treatment selection, we tended to recommend
IAC þ R for patients who strongly desired to retain their
bladder function. Additionally, during the 1980s, we often
recommended SC with a peplomycin-containing regimen
and radiotherapy. Finally, we explained the expected effi-
cacies and risks of our 3 methods and made treatment de-
cisions after consulting with the patients and their
families. We provided the patients with this information
and obtained written informed consent.
As shown in Fig. 1, among the 34 patients treated via SC,
cisplatin (CDDP)-based regimens were administered to 19
patients (55.9%). Carboplatin, 5-fluorouracil, and/orIAC
n ¼ 50
IAC þ R
n ¼ 79
p Value
) 38 (79.7) 63 (85.3) 0.582
) 14 (28.0) 45 (57.0) <0.001
3 (6.0) 8 (10.1) 0.716
) 12 (24.0) 15 (19.0) 0.463
) 2 (4.0) 9 (11.4) 0.218
) 25 (50.0) 49 (62.0) 0.399
0.014
) 33 (66.0) 37 (46.8)
) 13 (26.0) 22 (27.8)
) 4 (8.0) 20 (25.3)
) 17 (34.0) 42 (53.2) 0.008
) 4 (8.0) 7 (8.9) 0.833
) 34 (68.0) 50 (63.3) 0.120
) 49 (98.0) 75 (94.9) <0.001
) e 79 (100) e
) 29 (58.0) 30 (41.7) 0.061
) 17 (34.0) 14 (17.7) <0.001
) 17 (34.0) 20 (25.3) 0.469
; ECOG, Eastern Cooperative Oncology Group; PS, performance status;
complete; TUR, transurethral resection; chemo, chemotherapy.
Figure 1. Trial profile. Among 163 patients, 34 (20.9%) and 129 (79.1%) patients were treated with systematic chemotherapy and intra-arterial chemotherapy,
respectively. Among our treatment groups, the rates of pathological complete response in the complete IAC þ R group were higher than those in other treat-
ment groups.
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(44.1%) because of reduced renal function and the presence
of SCC.All patients received 2 0.3 cycles of chemotherapy,
and 18 (52.9%) patients were treated with radiotherapy after
the initial cycle of chemotherapy. Themean SD total radio-
therapy dose in the SC group was 21.1  11.1 Gy.
Overall, 129 patients (79.1%) received IAC via the
femoral artery. Digital subtraction angiography was per-
formed to determine the tumour blood supply, and agent
infusion was determined according to the major feeding ar-
tery. Two courses of chemotherapy with CDDP (70 mg/m2)
and doxorubicin (30 mg/m2; 1988e1994)/epirubicin
(30 mg/m2; 1993epresent) were administered in a
30e40-min sequence. A mean of 2  0.2 courses of
chemotherapy was administered, and each course of
chemotherapy was repeated approximately every 4 weeks.
For IAC þ R, radiotherapy began the day after chemo-
therapy administration, and the dose was delivered in 5
daily 2-Gy fractions per week by a megavoltage linear
accelerator (10-MV) for a 4-week period. A total dose of
40 Gy was administered to the urinary bladder and sur-
rounding tissues. However, the pelvic lymphatics of pa-
tients with N1 tumours were included in the radiotherapy
target area. Two-dimensional treatment was performed un-
til May 2002, and 3-dimensional treatment began in June
2002. Accordingly, we divided the patients into 2 groups
according to the treatment period for statistical analysis.
After a 4e8-week break, the treatment responses were
evaluated using ultrasonography, magnetic resonance imag-
ing, CT, cystoscopy, and cytological examination.Additionally, we recommended radical cystectomy, and pa-
tients who wished to undergo this underwent the procedure.
Patients who refused radical cystectomy underwent TUR
surgery. Finally, in this study, pCR was judged according
to the pathological examination results. Furthermore, we
recommended salvage cystectomy for patients who failed
to achieve a pCR. If these patients with residual tumours
did not agree to undergo radical surgery in this situation,
we performed additional chemotherapy, radiotherapy, and/
or a repeat-TUR (named adjuvant therapy in this study)
and again recommended radical cystectomy. To this chemo-
therapy, we added intra-vesicle chemotherapy to SC in some
patients with residual tumours that included non-MIBC.
Chest radiography and pelvic and abdominal CT were
performed every 6 months for 5 years after treatment and
annually for an additional 5 years. This protocol was
approved by the Human Ethics Review Committee of Na-
gasaki University Hospital. Additionally, we provided this
information to the patients and obtained written informed
consent.Statistical analysesData are expressed asmeans SD. Student’s t test and the
Scheffe test were used to analyze continuous variables and
multiple data comparisons respectively. The chi-square test
and Fisher’s exact test were used for categorical data com-
parisons. Survival rates were measured from the first day
of preoperative treatment to the day of patient death or last
patient contact. Survival was evaluated and analyzed using
364 Y. Miyata et al. / EJSO 41 (2015) 361e367KaplaneMeier curves and the log-rank p test. Variables that
achieved statistical significance ( p< 0.050) in univariate an-
alyses were subsequently entered into multivariate analysis,
which was conducted using a Cox proportional hazards
model. All statistical analyses were performed using the sta-
tistical software package StatView version 5.0 for Windows
(Abacus Concept, Inc., Berkeley, CA, USA).
ResultsClinicopathological featuresAs shown in Table 1, the frequency of older patients was
significantly higher in the IAC-R group than in the other
groups ( p < 0.001). Meanwhile, the frequency of high T-
stage tumours was significantly lower in the IAC group
than in the other groups ( p ¼ 0.008). Radical cystectomy
was performed in 26 (76.5%) patients in the SC group
but in only 14 (17.7%) in the IAC þ R group ( p < 0.001).Adverse eventsSevere toxicities occurred in 29 (36.7%) patients in the
IAC þ R group, and this incidence was significantly higher
( p ¼ 0.005) than those in the SC (n ¼ 6, 17.6%) and IAC
groups (n¼ 7, 16.0%). The most frequently occurring symp-
toms in all groups were haematological, including leucope-
nia and anaemia, and occurred in 14.7% (5/34), 14.0% (7/
50), and 22.8% (18/79) of patients in the SC, IAC, and
IAC þ R groups, respectively. However, the differences in
frequencies between the 3 groups did not reach statistical
significance ( p ¼ 0.374). On the other hand, the incidence
of urinary disorders such as urinary tract pain and haematuria
was remarkably higher in the IAC þ R group (n ¼ 14,
17.7%) than in the SC (0%) and IAC groups (n ¼ 3,
6.0%). Nearly all of these events improved after several
months of treatment; however, 27 of the IAC þ R patientsFigure 2. Rates of pathological complete responses (pCR) after chemotherapy and
icantly higher rate of pCR, compared with the other groups. In addition, the pCR r
incomplete IAC þ R group.(34.2%) required reduction in the chemotherapy doses and
radiotherapy intensities. Major adverse events that led to
dosage decreases in the IAC þ R group included altered
renal function, delayed haemorrhagic recovery, and vomit-
ing. Additionally, 18 of the 79 IAC þ R patients (22.8%)
required decreased dosages during the initial treatment due
to older age and/or the avoidance of severe adverse events.
Finally, 45 of the 79 IACþ R patients (57.0%) did not com-
plete the planned treatment. Therefore, we divided the
IACþ R patients into 2 subgroups, the incomplete and com-
plete IACþ R groups (latter:2 cycles of standard regimen
and 40 Gy of radiotherapy). Among the clinicopatholog-
ical features, significant differences were detected between
the incomplete IAC (n ¼ 45) and complete IAC þ R groups
(n ¼ 34) in terms of the frequencies of older age (32/45,
71.1% and 13/34, 38.2%; p ¼ 0.004) and recurrent tumours
(12/45, 26.7% and 3/34, 8.8%; p ¼ 0.045). There were no
other significant differences on clinicopathological features
between these 2 groups.Pathological complete responses in the local massAs shown in Fig. 2, pCR was achieved in 6 (17.6%), 11
(22.0%), and 34 (43.0%) patients in the SC, IAC, and
IAC þ R groups, respectively, with the highest incidence
in the IAC þ R group; this difference was significant
( p ¼ 0.007). In the IAC þ R subgroups, the pCR incidence
was significantly higher in the complete IAC þ R group
(19/34, 55.9%) than in the incomplete group (15/44,
33.3%; p < 0.001). Progressive disease was observed in 3
(8.8%) of the 34 SC patients. Therefore, 8 SC patients
(23.5%) received adjuvant therapy, including systemic
and intravesical chemotherapy. Additionally, in the SC
group, 1 of 8 patients (12.5%) who received conservative
treatment also underwent salvage cystectomy. Furthermore,
adjuvant therapy was also administered to 17 (34.0%) of
the 50 IAC patients, 13 (28.9%) of the 45 incompletechemoradiotherapy. The patients treated with IAC þ R exhibited a signif-
ate in the complete IAC þ R group was significantly higher than that in the
Figure 3. KaplaneMeier curves of overall (A) and cause-specific survival (B). In both analyses, the patients who completed the IAC þ R treatment had
significantly better survival. The mean  SD follow-up periods from the initial date of chemotherapy to the last available follow-up dates for the patients
treated with SC, IAC, and IAC þ R were 55.3  78.6, 58.3  66.7, and 46.5  54.0 months, respectively. Complete (Compl) IAC þ R, red; incomplete
(incompl) IAC þ R, orange; IAC, blue; SC, black line.
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IAC þ R patients. Salvage cystectomy was performed in
4 (12.1%) of the 33 IAC patients and 4 (10.8%) of the 37
incomplete IAC þ R patients. In contrast, in the complete
IAC þ R group, only 1 (3.6%) of the 28 patients underwent
salvage cystectomy.SurvivalTwelve (35.3%) of the 34 SC patients, 24 (48.0%) of the
50 IAC patients, and 16 (20.3%) of the 79 IAC þ R patients
died of bladder cancer. In contrast, only 2 (5.9%) of the 34
complete IAC þ R patients died of bladder cancer. The Ka-
planeMeier overall and cause-specific survival curves are
shown in Fig. 3. The 5-year overall survival rates in the
SC, IAC, and incomplete IAC þ R groups were 42.0%,
46.7%, and 50.3%, respectively. In contrast, the 5-year
overall survival rate of the complete IAC þ R group was
79.0%, and this was significantly better than the rates in
the other groups (log-rank p ¼ 0.037, Fig. 3A). Similarly,
for cause-specific survival, the complete IAC þ R patients
exhibited a better prognosis than did those who received
other treatments (log-rank p ¼ 0.014; Fig. 3B). A univariate
Cox proportional hazards analysis revealed significant asso-
ciations of N1 disease and complete IAC þ R treatment
with cause-specific survival (Table 2). A multivariate anal-
ysis model that included these 2 significant predictors
found that complete IAC þ R was an independent predic-
tive factor of cause-specific survival (hazard ratio
[HR] ¼ 0.16, 95% confidence interval [CI] ¼ 0.03e0.72,
p ¼ 0.028). In addition, in a multivariate analysis modelthat included all factors, N1 disease and complete
IAC þ R were also found to be significant predictive fac-
tors of cause-specific survival in patients with MIBC
(Table 2). Similar results were obtained for overall survival
in the univariate analysis. Additionally, a similar multivar-
iate analysis model that included all factors showed that
complete IAC þ R was a significant predictive factor for
overall survival in these patients (HR ¼ 0.27, 95%
CI ¼ 0.10e0.79, p ¼ 0.017).Discussion
Chemotherapy with or without radiotherapy has been
administered either as neo-adjuvant chemotherapy or as
bladder preservation therapy in patients with MIBC.9,10
Although the initial purposes of these 2 treatment strategies
differed, the results of these strategies often overlap with
respect to the antitumour effects and adverse events. For
example, although some patients receive chemotherapy as
a neo-adjuvant therapy before radical cystectomy, they
might refuse radical surgery because of downstaging after
treatment. In contrast, some patients who hope for bladder
preservation might undergo radical cystectomy because
multimodal therapy could not be completed owing to severe
adverse events. In fact, many patients in this study made
their final decisions after preoperative treatment. Therefore,
we analyzed all patients who received preoperative chemo-
therapy, regardless of initial intent.
Our results showed that the patients who received
IAC þ R had the highest pCR achievement rate. A well-
performed review found that the combination of
Table 2
Cause-specific survival analyses.
Univariate analysis Multivariate analysis
HR 95% CI p Value HR 95% CI p Value
Male 1.72 0.79e3.87 0.172 2.82 1.15e6.90 0.023
Old age (>75 years) 1.45 0.83e2.54 0.192 2.05 0.97e4.33 0.060
High ECOG PS (2) 1.48 0.53e4.15 0.453 0.86 0.28e2.70 0.801
Recurrent tumour 1.59 0.89e2.84 0.117 0.75 0.37e1.52 0.428
With SCC/AC 1.72 0.68e4.36 0.249 1.64 0.63e4.31 0.312
High grade 1.36 0.78e2.38 0.281 1.39 0.76e2.57 0.289
High T stage (T3/4) 0.97 0.56e1.67 0.915 0.91 0.47e1.79 0.791
N stage (N1) 2.73 1.21e6.16 0.015 4.47 1.73e11.58 0.002
Before 2002 0.65 0.33e1.08 0.089 0.54 0.26e1.12 0.098
CDDP-based regimens 0.97 0.44e2.15 0.932 0.69 0.25e1.93 0.477
With radiotherapy 1.12 0.65e1.93 0.689 0.91 0.45e1.83 0.794
Compl TUR before chemo 1.16 0.67e2.01 0.596 1.10 0.53e2.27 0.810
Cystectomy after chemo 0.59 0.31e1.12 0.107 0.51 0.25e1.06 0.070
Adjuvant therapy 0.53 0.25e1.13 0.100 e e e
Complete IAC þ R 0.16 0.04e0.70 0.015 0.15 0.03e0.77 0.024
HR, Hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SCC, squamous cell carcinoma; AC, adeno-
carcinoma; CDDP, cisplatin; compl, complete; TUR, transurethral resection; IAC þ R, intra-arterial chemotherapy and radiotherapy.
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local control and outcomes when compared with chemo-
therapy or radiotherapy alone.11 Therefore, many investiga-
tors have addressed the anti-cancer effects and adverse
events associated with these multimodal therapies and
have compared their results with those of others. However,
strict comparisons with other studies are very difficult
because of the wide variety in chemotherapeutic regimens,
radiotherapy methods, and patient backgrounds. For
example, regarding the chemotherapeutic regimens, some
studies used systemic MVEC (methotrexate/vinblastine/ep-
irubicin/cisplatin),9,12 MCV (methotrexate/cisplatin/
vinblastine),7,12,13 or other CDDP-based chemother-
apies.6,14,15 Moreover, non-CDDP-based regimens have
often been used for SC.8,16,17 In addition to SC, the intra-
arterial administration of chemotherapeutic agents6,14,18 or
both systemic and intra-arterial administration21 have also
been reported. Regarding the radiotherapy irradiation
range, several patterns have been reported, including the
bladder only,18 bladder plus surrounding tissues,10,16 and
bladder plus pelvis7,12,14,17,19 The irradiation intensity
also varies widely, with total doses to the pelvis of
<40 Gy,17,18 54e60 Gy,8 >60 Gy,7,9,12e16 and 40 Gy and
an additional 10e20 Gy to the bladder in cases with
massive tumours.19 Furthermore, patient selection was
divided into the following patterns: patients with T2 and
T36,9 or T2e4 disease7,8,13e15 and those with N07,9,13,14
or N1 disease.8,12 In reality, these multimodal therapies
yielded a wide range of CR achievement rates from
39.3% to 90.3%.7e19 Similarly, the 3-year overall survival
rates associated with these bladder preservation therapies
were reported to range from 47% to 83%.15,20 Therefore,
it does not seem logical to clarify the antitumour effects
of each treatment tool used in multimodal therapies. In
contrast, our study was conducted according to a unifiedpolicy at a single hospital. Accordingly, we believe that
our results present more accurate differences in the anti-
cancer effects and adverse events associated with the
administration route or use of additional radiotherapy in pa-
tients with MIBC.
In the present study, the overall and cause-specific 5-
year survival rates of patients who received complete
IAC þ R were 79.0% and 87.2%, respectively. A possible
reason for this improved prognosis is that IAC þ R was
successfully completed by patients with a better general
condition and higher organ-sparing ability. Additionally,
we emphasize the importance of receiving the full planned
doses of chemotherapy and radiotherapy. A similar opinion
was suggested by another study in which a reduced chemo-
radiotherapy dose was found to be a significant predictor of
reduced survival in patients with MIBC.8
Urinary disorders were more characteristic of the
IAC þ R group than of the other groups. Given the fact
that the frequency of this symptom was remarkably higher
in the IAC þ R group than in the IAC group, the addition of
radiotherapy to IAC is thought to be associated partly with
the occurrence of these urological symptoms. However,
such high incidences of urinary disorders were not reported
in previous reports of combined SC and radiotherapy.10
Furthermore, an earlier report stated that urinary complica-
tions of chemoradiotherapy occurred in 11.5% of cases, a
frequency similar to that achieved with radiotherapy alone.7
Given these results, it is possible that radiotherapy, when
administered along with higher concentrations of anticarci-
nogenic agent(s) delivered via intra-arterial infusion, is
associated with the incidence of urinary disorders.
The European Association of Urology (EAU) guidelines
mention the effectiveness and unknown issues of neo-
adjuvant therapy and bladder-sparing treatments for local-
ized disease.21 However, the guideline recommendations
367Y. Miyata et al. / EJSO 41 (2015) 361e367and conclusions are based on results obtained with SC
because this method is common, and information regarding
IAC is too scarce. Therefore, we believe that our results are
useful when discussing treatment strategies that include
IAC. On the other hand, a limitation of this study is a treat-
ment selection bias due to the lack of fixed criteria. Addi-
tionally, the relatively small number of patients in each
group and differences in the patients’ backgrounds, radio-
therapy strategies, treatments after chemotherapy, and
follow-up strategies after cystectomy are also potential
sources of bias, given the retrospective nature of this
study.22 Furthermore, the radiotherapy intensity used in
this study differs from the recommended intensity in the
EAU guidelines.21 Therefore, further studies, including a
randomized study and a well-designed larger study, will
be necessary to determine the usefulness of these therapies
in patients with MIBC.
In conclusion, multimodal IAC þ R therapy was found
to be a useful therapeutic strategy for patients with
MIBC. In particular, completion of the planned treatment
was a key predictive factor of survival in these patients.
Furthermore, a solution for addressing the adverse events
and the development of countermeasures are important
and necessary to increase the use of IAC þ R.
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